B+
Bull case
15%
Probability
Target price
$1.10
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
KTTA
Pasithea TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The June 30 company update reported 34 advanced-cancer patients, no dose-limiting toxicities, no treatment-related discontinuations, and durable stable disease in several heavily pretreated patients; the ESMO presentation is the clearest potential rerating trigger [#IR-2026-06-30].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Coverage is low and no reliable post-earnings consensus surprise, analyst revision, or attributed market-reaction data was available.
Momentum
83
Value
57
Sentiment
50
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.50 · Bull $1.10 · Bear $0.20Analysis 2026-08-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $3.00
Why
Momentum83 · Δ7d -
Value57 · Δ7d -0.0
Sentiment50 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Coverage is low and no reliable post-earnings consensus surprise, analyst revision, or attributed market-reaction data was available.
- • Early clinical signals may not translate into confirmed efficacy or regulatory approval; the company explicitly notes that future results may be negative or ambiguous [#IR-2026-06-30].
- • Clinical efficacy remains preliminary and uncontrolled, final progression-free-survival data are not yet known, and the Q2 filing shows ongoing losses, $9.5 million of six-month operating cash burn, and dependence on future equity or debt funding [#SEC-10Q-2026-08-14].
Catalyst clock
2026-08-14
Q2 2026 liquidity checkpoint
Lead driver: Sentiment · See AI snapshot
Momentum
83
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.4
Sentiment
50
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 83.4 / Value 57.4 / Sentiment 49.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-17. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$0.50
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.20
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$15.97M
Beta
0.22
Shares Out
33.41M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.40
Rev YoY
-100.0%
EPS YoY
-75.1%
Gross Margin
-21.0%
Op Margin
-
Net Debt
-$55.26M
Current Ratio
26.25
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data